Boston's world-class hepatology centres at Massachusetts General Hospital and Beth Israel Deaconess manage significant Hepatitis C patient populations. For those facing insurance barriers or high out-of-pocket costs, Resof L offers the same proven cure at dramatically reduced cost.
Resof L achieves SVR12 cure rates above 95% in Genotype 1 HCV patients — the most common genotype in the United States. The standard 12-week treatment course costs under $500 from Unnati Pharmax, compared to over $84,000 for brand Harvoni in US pharmacies.
Boston's significant international student and immigrant populations, many from HCV-endemic regions, make affordable generic HCV treatment access particularly important in this market.
❓ FAQ: What happens after I complete my Resof L treatment — am I immediately cured?
Treatment completion is just the first step. Confirmation of cure requires a follow-up blood test 12 weeks after finishing treatment, checking for SVR12 (sustained virologic response at 12 weeks). If HCV remains undetectable at that point, you are considered cured. Your Boston hepatologist will schedule this follow-up test as part of standard post-treatment care.